Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Stable Atherosclerotic Vascular Diseases
NCT06986369Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in coronary artery disease (CAD), peripheral artery disease (PAD), sponsored by The University of Hong Kong. Started May 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT06986369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986369.